In Depth 25 Jan 2024 The trends that will shape the biotech industry in 2024 …Alzheimer’s, is also gaining traction. The potential of these technologies in such diverse applications highlights the significant role stem cells are expected to play in the future of biotech. Overall,… January 25, 2024 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 May 2024 Eight companies spearheading Philadelphia’s biotech industry …(ALS) and Alzheimer’s disease. Passage Bio is also developing gene therapies for GM1 gangliosidosis, Krabbe disease, metachromatic leukodystrophy (MLD), and other neurodegenerative conditions. Verismo Therapeutics Verismo Therapeutics, founded in 2022… May 21, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 25 Apr 2019 European Biotechnology in 2019 and Beyond: What’s Hot and What’s Not? …noted King “With last week’s failure of the Alzheimer’s drug from Biogen, we see that we really need different, transformative approaches in neuroscience. For me, gene therapy in the brain… April 25, 2019 - 11 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jun 2021 The Top European Biotech Investment Rounds in May …diabetes drug semaglutide became the first FDA-approved obesity treatment since 2014. And this week’s stunning FDA approval of Biogen’s controversial Alzheimer’s treatment aducanumab could revitalize investor interest in drugs aiming… June 10, 2021 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 13 Sep 2022 Research charity calls on scientists, engineers, and technology experts to transform dialysis treatment …including Bayer Crop Science, Johnson & Johnson, Murata Manufacturing, Johnson Matthey, Air Products, GSK Consumer Healthcare, as well as medical research charities including Alzheimer’s Research UK and Kidney Research UK…. September 13, 2022 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 26 Sep 2025 Can biotechnology reduce animal testing in medicine? …as Alzheimer’s, where many drugs have failed in clinical trials after showing promise in animal testing. “One reason for this [why drugs fail despite promising preclinical results] is that animals… September 26, 2025 - 14 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2016 Meet the French CEO who wants to Break Barriers to Drug Delivery …treat neurological disorders like Alzheimer’s disease, stroke and multiple sclerosis. However, the blood-brain barrier (BBB), which prevents most toxic molecules and infectious agents from entering the brain, also heavily restricts… October 10, 2016 - 5 minutesmins - By Marie Godar Share WhatsApp Twitter Linkedin Email
News and Trends 28 Aug 2024 GLP-1 shortage: Can biotech companies keep up with rising demand? …and obesity, Alzheimer’s disease, cancer and autoimmune conditions. Our acquisition of the injectable manufacturing facility in Wisconsin is an excellent example of our strategy to meet those demands,” said a… August 28, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2023 Roche and Alnylam to work on RNAi therapeutic to treat hypertension …including stroke (ischaemic and haemorrhagic), coronary artery disease, heart failure, peripheral artery disease, chronic kidney disease and end-stage renal disease, dementia, and Alzheimer’s disease. Despite management strategies such as lifestyle… July 25, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Weekly Roundup 15 Dec 2023 Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered …evaluated in a phase 1 Alzheimer’s disease program. AstraZeneca to purchase vaccine developer Icosavax AstraZeneca announced its prospective acquisition of Icosavax, earlier this week. American vaccine maker Icosavax, has created… December 15, 2023 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 4 Sep 2017 Record Momentum for European Biotech …and chronic diseases, such as diabetes type 2 and alzheimer’s disease (AD). And although there had been a lull in the study of gene therapies, they experienced their come-back when… September 4, 2017 - 10 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2018 Two Proteins in the Brain Could Protect Against and Repair the Damage Caused by Parkinson’s …Alzheimers and ALS, is proving a massive challenge for biotech and pharma alike. Let’s hope that these findings provide us with the help that we so badly need, with patients… January 16, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email